Tumors with the loss of heterozygosity in either the BRCA1 or 2 gene correspondingly show defects in repairing double-strand DNA breaks, and are sensitive to inhibitors of PARP1, an enzyme that contributes to repairing single-strand DNA breaks, by causing the synthetic lethality of tumor cells. Here, BRCA1 is linked to neoplasm.